News


Kymab Expands Infectious Disease Programmes

Kymab receives $9m grant from the Bill & Melinda Gates Foundation to fund infectious disease research and development

Kymab Group Limited, a leading monoclonal antibody biopharmaceutical group, announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.